Disclosures for "Long-term Function and Survival of Radicava ORS® (Oral Edaravone)-Treated Patients With ALS vs Propensity Score–Matched PRO-ACT Historical Controls"
-
Dr. Takahashi has nothing to disclose.
-
Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for pepgen. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
-
Mr. Yoneoka has nothing to disclose.
-
Mr. Hirai has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America.
-
Mr. Selness has received personal compensation for serving as an employee of Mitsubishi Tanabe.
-
Dr. Todorovic has nothing to disclose.
-
Dr. Wamil has received personal compensation for serving as an employee of Mitsubishi Tanabe.
-
Mr. Sasson has nothing to disclose.
-
Stephen Apple has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc.
-
Mr. ?? has nothing to disclose.